Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.68 |
| ▸ | DPP4 known ✓ | P27487 | 5/20 | 0.53 |
| ▸ | KCNH2 known ✓ | Q12809 | 3/20 | 0.53 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.50 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.50 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.50 |
| ▸ | ITGB3 known ✓ | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B known ✓ | P08514 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.61 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.53 |
| ▸ | TLR4 | O00206 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7617 | 0.99 | ALDH1A1 (0.70) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL2520795 | 0.93 | EPHX1 (0.64) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL4072126 | 0.93 | EPHX1 (0.64) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL2522491 | 0.93 | EPHX1 (0.64) | ALDH1A1GAATSHREPHX1CTSL | |
| Hydrochloric Acid SCHEMBL2854037 | 0.92 | ALDH1A1 (0.61) | ALDH1A1GAATSHREPHX1CTSL | |
| Hydrochloric Acid SCHEMBL243635 | 0.92 | ALDH1A1 (0.61) | ALDH1A1GAATSHREPHX1CTSL | |
| Hydrochloric Acid SCHEMBL243634 | 0.92 | ALDH1A1 (0.61) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL2901586 | 0.90 | ALDH1A1 (0.63) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL240039 | 0.90 | ALDH1A1 (0.63) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL240038 | 0.90 | ALDH1A1 (0.63) | ALDH1A1GAATSHREPHX1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111848598-B | Heterocyclic compound, application thereof and composition containing same | 健艾仕生物医药有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-111936468-B | Compounds with anticancer activity | 协和麒麟株式会社 | 2024-03-08 | — | — | CN | disclosed |
| CN-110214141-B | Benzodiazolium compounds as ENaC inhibitors | 企业治疗学有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-114502534-A | BET degradant | 协和麒麟株式会社 | 2022-05-13 | — | — | CN | disclosed |
| EP-3794002-A1 | COMPOUNDS | Enterprise Therapeutics Limited (GB) | 2021-03-24 | — | — | EP | disclosed |
| CN-111936468-A | Compounds with anti-cancer activity | 协和麒麟株式会社 | 2020-11-13 | — | — | CN | disclosed |
| WO-2015161011-A1 | BENZAMIDE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | WO | disclosed |
| WO-2014160177-A2 | QUINAZOLINE INHIBITORS OF PI3K | EXELIXIS, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20120040897-A1 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2012-02-16 | — | — | US | disclosed |
| WO-2010126820-A2 | PREPARATION OF ALKYL ESTERS OF N-PROTECTED OXO-AZACYCLOALKYLCARBOXYLIC ACIDS | MERCK SHARP & DOHME CORP. (US) | 2010-11-04 | — | — | WO | disclosed |
| EP-2231687-A2 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES | Sun Pharma Advanced Research Company Limited (IN) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009116067-A2 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040897-A1 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES | NR1D2, STARD10, NR1D1 | GAA 4284/4885DPP4 3186/4885KCNH2 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.